Each film coated tablet contains flavoxate hydrochloride 200mg

Flavoxate hydrochloride is a flavone derivative.

The basic action of Urispas is the relaxation of smooth muscle fibres of the urinary tract

Urispas is indicated for the symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as many occur in cystitis, prostatitis, urethritis, urethrocystitis, and urethrotrigonitis.

DOSAGE AND ADMINSTRATION

Adult and children over 12 years of age :  200 mg 3 – 4 times a day.

With improvement of symptoms, the dose may be reduced.

PRECAUTIONS

Urispas should be given cautiously to patiensts with suspected glaucoma. The drug should only be used during pregnancy if the anticipated benefits outweigh any risk. Not recommended for infants and children under 12 years of age since safety and efficacy studies in this age group are not completed.

In the event of drowsiness or blurred vision, the patients should not operate a motor wehicle or any machinery, and refrain from participating in activites requiring alertness. If overdosage occur, maximus 4 hours after overdosage, evacuation of the stomach should be performed. If overdosage is extreme, or there is a delay in removing the drug from the stomach, administration of a parasympathomimetic drug should be considered. Administration in nursing mother only if clearly needed.

ADVERSE REACTION

Nausea, vomiting, dry mouth, nervousness vertigo, headache, drowsiness, blurred vision, increased ocular tension, disturbance in eye accommodation, mental confusion, dysuria, tachycardia, palpitation, hyperpurexia, eosinophilia, leukopenia, urticarial and other dermatoses.

URISPAS is contraindication in pationts who have any of the following conditions; pyloric or duodenal obstrucion, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.

STORAGE

Keep in a cool and dry place

PRESENTATION

Box, 3 blister @10 film coated tablet

RECODARTI S.p.A.